Accueil > Événements > Séminaires

Séminaire IBMM

Targeted nanoparticles for therapeutic applications

Dr. Frank Alexis (Massachusetts Institute of Technology, Cambridge, USA & Brigham and Women’s Hospital, Harvard Medical School, Boston, USA)

publié le , mis à jour le

Le Mardi 27 Mai 2008 à 14h30
Amphithéâtre C de la Faculté de Pharmacie

Nanotechnology – the engineering and manufacturing of materials using atomic and molecular components – is expected to benefit all branches of medicine. The breakthrough potential of nanotechnology is becoming more apparent with several examples of non-targeted NPs in clinical practice today. Drug/gene encapsulated nanoparticles (NPs) have the potential to improve the current therapies by increasing drug/gene efficacy, lowering drug toxicity, cross barriers and maintaining a high local concentration of drug over an extended period of time. These biodegradable targeted nanoparticles are internalized via receptor mediated mechanisms into specific type of cells.

Two approaches will be presented for cancer therapy. For example, targeted nanoparticle-aptamer bioconjugates drug delivery systems for prostate cancer therapy will be discussed. Similarly, proof of concept of targeted nanoparticle-affibody bioconjugates for therapy of multiple types of cancers will be presented. Last, data about receptor mediated mechanisms to cross cell barriers using targeted nanoparticles shows potential therapeutic applications for oral drug delivery and cardiovascular diseases.

Finally, a short introduction of Clemson University and Clemson Bioengineering department will be presented for the recruitment of possible PhD candidates and attachment students.


Ajouter un événement iCal